Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 8241628 Compositions and methods for antibodies targeting complement protein C5

Patent 8241628 was granted and assigned to Novartis on August, 2012 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

August 14, 2012

Patent Application Number

12535205

Date Filed

August 4, 2009

Patent Citations Received

US Patent 12128101 Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS)

0

US Patent 12025621 Atypical hemolytic uremic syndrome (AHUS) biomarker proteins

0

US Patent 12076319 Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria

0

US Patent 12084516 Anti-C5 antibody combinations and uses thereof

0

US Patent 11708351 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

0

US Patent 11783645 Multi-camera, multi-sensor panel data extraction system and method

US Patent 11861904 Automatic versioning of video presentations

0

US Patent 11863858 Automatic camera angle switching in response to low noise audio to create combined audiovisual file

0

...

Patent Primary Examiner

Patent abstract

The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8241628 Compositions and methods for antibodies targeting complement protein C5

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool